tradingkey.logo

Longeveron Inc

LGVN
0.510USD
-0.003-0.66%
시장 운영 시간 ET시세는 15분 지연됩니다
10.73M시가총액
손실P/E TTM

Longeveron Inc

0.510
-0.003-0.66%

자세한 내용은 Longeveron Inc 회사

Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.

Longeveron Inc 정보

종목 코드 LGVN
회사 이름Longeveron Inc
상장일Feb 12, 2021
CEOPowell (Than)
직원 수25
유형Ordinary Share
회계 연도 종료Feb 12
주소1951 NW 7th Ave
도시MIAMI
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호33136
전화13053027158
웹사이트https://www.longeveron.com/
종목 코드 LGVN
상장일Feb 12, 2021
CEOPowell (Than)

Longeveron Inc의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-5250.00%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
142.17K
-10250.00%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
129.90K
-10250.00%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
91.84K
-10700.00%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
35.55K
+17000.00%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+17000.00%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
21.00K
+17000.00%
Mr. Rock Soffer
Mr. Rock Soffer
Director
Director
--
--
Mr. Paul Lehr, J.D.
Mr. Paul Lehr, J.D.
General Counsel and Secretary
General Counsel and Secretary
--
--
Mr. Than Powell
Mr. Than Powell
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Executive Chairman of the Board, Co-Founder, Chief Science Officer
Executive Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-5250.00%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
142.17K
-10250.00%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
129.90K
-10250.00%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
91.84K
-10700.00%
Ms. Ursula Ungaro, J.D.
Ms. Ursula Ungaro, J.D.
Independent Director
Independent Director
35.55K
+17000.00%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+17000.00%

수익 분석

통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
사업별USD
이름
수익
비율
Clinical trial revenue
94.00K
68.61%
Contract manufacturing
37.00K
27.01%
Contract manufacturing lease revenue
6.00K
4.38%
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
사업별USD
이름
수익
비율
Clinical trial revenue
94.00K
68.61%
Contract manufacturing
37.00K
27.01%
Contract manufacturing lease revenue
6.00K
4.38%

주식 보유 통계

마지막 업데이트: Sun, Nov 16
마지막 업데이트: Sun, Nov 16
주주
주주 유형
주주
주주
비율
Lincoln Alternative Strategies LLC
5.93%
Armistice Capital LLC
3.41%
The Vanguard Group, Inc.
2.51%
Lehr (Paul T)
1.60%
Hashad (Mohamed Wa'el Ahmed)
1.57%
기타
84.98%
주주
주주
비율
Lincoln Alternative Strategies LLC
5.93%
Armistice Capital LLC
3.41%
The Vanguard Group, Inc.
2.51%
Lehr (Paul T)
1.60%
Hashad (Mohamed Wa'el Ahmed)
1.57%
기타
84.98%
주주 유형
주주
비율
Individual Investor
8.93%
Corporation
5.93%
Hedge Fund
3.77%
Investment Advisor
3.48%
Investment Advisor/Hedge Fund
1.08%
Research Firm
0.30%
기타
76.53%

기관 주식 보유

마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
59
1.71M
8.62%
+623.94K
2025Q3
58
1.73M
8.71%
+931.02K
2025Q2
73
2.18M
16.11%
+296.38K
2025Q1
73
2.14M
15.82%
-119.71K
2024Q4
73
2.53M
18.80%
+652.31K
2024Q3
67
2.33M
17.58%
+1.38M
2024Q2
67
924.88K
16.16%
+194.99K
2024Q1
64
168.05K
15.95%
-258.83K
2023Q4
68
363.47K
37.19%
+110.22K
2023Q3
73
198.13K
31.46%
-72.89K
더 보기

주주 활동

이름
보유 주식
비율
변동
Chg %
날짜
Lincoln Alternative Strategies LLC
1.18M
5.93%
+1.18M
--
Aug 08, 2025
Armistice Capital LLC
676.23K
3.41%
+676.23K
--
Sep 30, 2024
The Vanguard Group, Inc.
505.57K
2.55%
+361.30K
+250.43%
Sep 30, 2025
Lehr (Paul T)
325.36K
1.64%
-4.94K
-1.50%
Oct 01, 2025
Hashad (Mohamed Wa'el Ahmed)
310.90K
1.57%
+166.85K
+115.83%
Jul 15, 2025
Hare (Joshua M)
253.07K
1.27%
-5.25K
-2.03%
May 16, 2025
Soffer (Rock J)
179.52K
0.9%
+17.00K
+10.46%
Jul 15, 2025
Locklear (Lisa)
152.42K
0.77%
-11.88K
-7.23%
Oct 01, 2025
Geode Capital Management, L.L.C.
141.50K
0.71%
--
--
Sep 30, 2025
Agafonova (Nataliya)
140.15K
0.71%
-11.88K
-7.82%
Oct 01, 2025
더 보기

관련 ETF

마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
비율0%

주식 배당금

지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음

주식 분할

날짜
배당락일
유형
비율
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
날짜
배당락일
유형
비율
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
Mar 19, 2024
Merger
10→1
KeyAI